UY24897A1 - (s) - atropisomeros de 3-aril-4(3h)-quinazolinonas - Google Patents

(s) - atropisomeros de 3-aril-4(3h)-quinazolinonas

Info

Publication number
UY24897A1
UY24897A1 UY24897A UY24897A UY24897A1 UY 24897 A1 UY24897 A1 UY 24897A1 UY 24897 A UY24897 A UY 24897A UY 24897 A UY24897 A UY 24897A UY 24897 A1 UY24897 A1 UY 24897A1
Authority
UY
Uruguay
Prior art keywords
fluoro
phenyl
quinazolin
halo
vinyl
Prior art date
Application number
UY24897A
Other languages
English (en)
Inventor
Keith Michael Devries
Willard Mckowan Welch Jr
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY24897A1 publication Critical patent/UY24897A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

Atropisómeros (S) con relación al carbono marcado con el asterisco, de fórmula (Ia) representada en la figura 1, y sus sales farmacéuticamente aceptables en donde: R2 es un heterociclo de 5 o 6 miembros, representado en la figura 2; las posiciones "K", "L", y "M" en dicho anillo pueden estar seleccionadas de manera independiente de entre carbono o nitrógeno; R3 es hidrógeno o halo; R5 es halo; R6, R7 y R8 son hidrógeno. Ejemplos no limitantes de compuestos preferidos: (S)-3-(2-cloro-fenil)-2-[2-(5-dimetilaminometil-2-fluoro-fenil)-vinil]-6-fluoro-3H-quinazolin-4-ona; (S)-6-fluoro-2-[2-(2-metil-tiazol-4-il)-vinil]-3-(2-metil-fenil)-3H-quinazolin-4-ona. Una composición farmacéutica de estos compuestos son de utilidad en el tratamiento de afecciones neurodegenerativas y relacionadas con traumas del SNC, como también para prevenir una afección seleccionada entre déficits cerebrales posteriores o resultantes de una cirugía de desviación cardíaca e injertos.
UY24897A 1997-02-28 1998-02-20 (s) - atropisomeros de 3-aril-4(3h)-quinazolinonas UY24897A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3890597P 1997-02-28 1997-02-28

Publications (1)

Publication Number Publication Date
UY24897A1 true UY24897A1 (es) 2000-12-29

Family

ID=21902563

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24897A UY24897A1 (es) 1997-02-28 1998-02-20 (s) - atropisomeros de 3-aril-4(3h)-quinazolinonas

Country Status (40)

Country Link
US (1) US6306864B1 (es)
EP (1) EP0968194B1 (es)
JP (1) JP2000509731A (es)
KR (1) KR100358636B1 (es)
CN (1) CN1248248A (es)
AP (1) AP859A (es)
AR (1) AR011170A1 (es)
AT (1) ATE267817T1 (es)
AU (1) AU744028B2 (es)
BG (1) BG103689A (es)
BR (1) BR9807872A (es)
CA (1) CA2282277C (es)
DE (1) DE69824157T2 (es)
DK (1) DK0968194T3 (es)
DZ (1) DZ2440A1 (es)
EA (1) EA001963B1 (es)
ES (1) ES2219866T3 (es)
GT (1) GT199800038A (es)
HR (1) HRP980106A2 (es)
HU (1) HUP0000914A3 (es)
ID (1) ID22711A (es)
IL (1) IL130900A0 (es)
IS (1) IS1952B (es)
MA (1) MA24484A1 (es)
NO (1) NO313630B1 (es)
NZ (1) NZ336628A (es)
OA (1) OA11089A (es)
PA (1) PA8447001A1 (es)
PE (1) PE58399A1 (es)
PL (1) PL335418A1 (es)
PT (1) PT968194E (es)
SK (1) SK113299A3 (es)
TN (1) TNSN98035A1 (es)
TR (1) TR199902093T2 (es)
TW (1) TW504508B (es)
UA (1) UA61097C2 (es)
UY (1) UY24897A1 (es)
WO (1) WO1998038173A1 (es)
YU (1) YU41299A (es)
ZA (1) ZA981666B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199802296T2 (xx) 1996-05-15 1999-02-22 Pfizer Inc. Yeni 2,3 dis�bstit�te-4 (3H)-kinazolinonlar
US6323208B1 (en) * 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
JPH11279158A (ja) * 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―４―オン誘導体の製造方法
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CN1440408B (zh) * 2000-04-25 2012-07-18 艾科斯有限公司 人磷脂酰肌醇3-激酶δ的抑制剂
HU229553B1 (en) 2000-06-12 2014-01-28 Eisai R & D Man Co 1,2-dihydropyridine compound, process for preparation of the same and use thereof
HU228914B1 (hu) 2000-08-18 2013-06-28 Ajinomoto Kk Fenilalanin-származékok
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US6939968B2 (en) * 2002-12-23 2005-09-06 Bristol-Myers Squibb Company Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
US20080146562A1 (en) * 2003-08-08 2008-06-19 Ulysses Pharmaceutical Products Inc., Halogenated quinazolinyl nitrofurans as antibacterial agents
JP2007501809A (ja) * 2003-08-08 2007-02-01 ユリシーズ・ファーマシューティカル・プロダクツ・インコーポレイテッド 抗菌剤としてのハロゲン化キナゾリニルニトロフラン
GB0325390D0 (en) * 2003-10-30 2003-12-03 Novartis Ag Organic compounds
NZ548420A (en) 2003-12-22 2010-03-26 Ajinomoto Kk Novel phenylalanine derivative
EP1761540B1 (en) 2004-05-13 2016-09-28 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
GB0416730D0 (en) * 2004-07-27 2004-09-01 Novartis Ag Organic compounds
WO2007056124A2 (en) 2005-11-04 2007-05-18 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
EP2079739A2 (en) 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
CN101429166B (zh) * 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CA2975473C (en) 2008-11-13 2021-01-19 Gilead Calistoga Llc Therapies for hematologic malignancies
PE20120602A1 (es) 2009-03-24 2012-05-21 Gilead Calistoga Llc ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
KR20120049281A (ko) 2009-07-21 2012-05-16 길리아드 칼리스토가 엘엘씨 Ｐｉ３ｋ 억제제를 이용한 간 장애의 치료
CN104334560A (zh) 2012-03-05 2015-02-04 吉利德卡利斯托加有限责任公司 (s)-2-(1-(9h-嘌呤-6-基氨基)丙基)-5-氟-3-苯基喹唑啉-4(3h)-酮的多晶型物
CN103275086B (zh) * 2013-05-30 2015-04-15 温州大学 一种6-取代喹唑啉并喹唑啉酮化合物及其合成方法和用途
EA201690990A1 (ru) 2013-12-20 2016-11-30 Джилид Калистога Ллс Способы получения ингибиторов фосфатидилинозитол-3-киназы
AU2014364414A1 (en) 2013-12-20 2016-06-30 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
US9533909B2 (en) 2014-03-31 2017-01-03 Corning Incorporated Methods and apparatus for material processing using atmospheric thermal plasma reactor
NZ726360A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
DE102014217021A1 (de) * 2014-08-27 2016-03-03 Skf Lubrication Systems Germany Ag Gehäuse für eine Vorrichtung zum dosierten Verteilen eines Mediums sowie eine Dosiereinrichtung zur Verwendung in dem Gehäuse
CA3122705A1 (en) 2018-12-14 2020-06-18 Eisai R&D Management Co., Ltd. Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds
JP2023512664A (ja) 2020-01-29 2023-03-28 カマリ ファーマ リミテッド 皮膚障害の治療に使用するための化合物及び組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195321B (de) * 1962-03-16 1965-06-24 Troponwerke Dinklage & Co Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten
DE1670416A1 (de) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
US3748325A (en) * 1970-04-06 1973-07-24 Karamchand Premchand Private Process for the preparation of quinazolinone derivatives
US4183931A (en) * 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
GB9022785D0 (en) * 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
WO1992013535A1 (en) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5777271A (en) * 1996-01-18 1998-07-07 Commscope, Inc. Cable having an at least partially oxidized armor layer
TR199802296T2 (xx) * 1996-05-15 1999-02-22 Pfizer Inc. Yeni 2,3 dis�bstit�te-4 (3H)-kinazolinonlar

Also Published As

Publication number Publication date
MA24484A1 (fr) 1998-10-01
WO1998038173A1 (en) 1998-09-03
AR011170A1 (es) 2000-08-02
CA2282277A1 (en) 1998-09-03
NO994177L (no) 1999-08-27
DK0968194T3 (da) 2004-08-16
HUP0000914A2 (hu) 2001-04-28
EA001963B1 (ru) 2001-10-22
ES2219866T3 (es) 2004-12-01
PE58399A1 (es) 1999-06-16
EP0968194B1 (en) 2004-05-26
TW504508B (en) 2002-10-01
JP2000509731A (ja) 2000-08-02
HUP0000914A3 (en) 2001-09-28
AP9801199A0 (en) 1998-03-31
BR9807872A (pt) 2000-03-21
GT199800038A (es) 1999-08-13
KR20000075814A (ko) 2000-12-26
IS1952B (is) 2004-10-13
IL130900A0 (en) 2001-01-28
ATE267817T1 (de) 2004-06-15
EA199900693A1 (ru) 2000-02-28
NO994177D0 (no) 1999-08-27
OA11089A (en) 2003-09-22
PL335418A1 (en) 2000-04-25
IS5140A (is) 1999-07-30
KR100358636B1 (ko) 2002-10-31
BG103689A (bg) 2000-11-30
AP859A (en) 2000-07-21
PT968194E (pt) 2004-08-31
DZ2440A1 (fr) 2003-01-11
TR199902093T2 (xx) 1999-12-21
DE69824157D1 (de) 2004-07-01
HRP980106A2 (en) 1999-02-28
ID22711A (id) 1999-12-09
NO313630B1 (no) 2002-11-04
PA8447001A1 (es) 2000-05-24
EP0968194A1 (en) 2000-01-05
AU744028B2 (en) 2002-02-14
AU5676898A (en) 1998-09-18
ZA981666B (en) 1999-08-27
YU41299A (sh) 2002-09-19
SK113299A3 (en) 2001-05-10
CA2282277C (en) 2005-10-11
CN1248248A (zh) 2000-03-22
NZ336628A (en) 2001-03-30
TNSN98035A1 (fr) 2005-03-15
UA61097C2 (uk) 2003-11-17
DE69824157T2 (de) 2004-10-14
US6306864B1 (en) 2001-10-23

Similar Documents

Publication Publication Date Title
UY24897A1 (es) (s) - atropisomeros de 3-aril-4(3h)-quinazolinonas
ATE157005T1 (de) Verwendung von sertindol zur behandlung von schizophrenie
SE9904176D0 (sv) New use
SE9903760D0 (sv) New compounds
HUP9902148A2 (hu) Új 2,3-diszubsztituált-4(3H)-kinazolinonok
PH25571A (en) Alpha'-alkyl-4-amino-3-quinolinemethanols, 1-(4-aralkylamino-3-quinolinyl) alaknones, their use as medicaments
NO180488C (no) Benzoisothiazol og benzoisoksazol-3-karboksamider og deres bruk til fremstilling av medikamenter
ATE102930T1 (de) Heterozyklische verbindungen, deren herstellung und medikamente diese enthaltend.
ES2165360T3 (es) Cicloalquenos y cicloalcanos 1,3-sustituidos como agentes del sistema nervioso central.
ATE327225T1 (de) Neue verwendung von benzothiazolderivaten
MX9307332A (es) 3-(aminoalquilamino)-1,2-bencisoxasoles substituidos y compuestos relacionados.
NO894742D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tiadiazoler, oksadiazoler og triazoler.
ATE211729T1 (de) Therapeutisch wirksame verbindungen
DK0765320T3 (da) Benzimidazolonderivater med central dopaminerg aktivitet
DE69413118D1 (de) Benzolsulfonamid-Derivate zur Behandlung der Blaseninstabilität
HU9201887D0 (en) Process for the production of //aralkyl-piperidine-4-yl/-methyl/-2a,3,4,5-tetrahydro-1-/2h/-acenaphtylene-1-on derivatives and of medical preparations containing them as active agents
FI970469A0 (fi) Bentsimidatsolijohdannaisia, joilla on dopaminerginen aktiivisuus
HU9201290D0 (en) 1-/pirido/3,4-b/-1,4-oxazinyl-4-yl/-1h-indole derivatives, process for their production and for the production of medical preparations containing them as active agents
DK557189A (da) 1,2,3,4-tetrahydro-1,9-acridindiaminer, deres fremstilling og anvendelse som laegemidler
NO913543D0 (no) Fremgangsmaate for fremstilling av 3-(1h-indazol-3-yl)-4-pyridinaminer og mellomprodukter, og anvendelse som medikamenter.
FI895605A0 (fi) Menetelmä lääkeaineina käyttökelpoisten 3a,4,5,6-tetrahydro-(3H)-pyrimidino/4,5,6-k,l/akridiinien valmistamiseksi
NO20012538L (no) Anvendelse av N-substituerte azabicycloalkanderivater for behandling av forstyrrelser i sentralnervesystemet
UY26400A1 (es) Derivados de las benzodiazepinas
UY26401A1 (es) Derivados de la benzodiazepinas

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20041105